[go: up one dir, main page]

WO1988008704A3 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
WO1988008704A3
WO1988008704A3 PCT/GB1988/000350 GB8800350W WO8808704A3 WO 1988008704 A3 WO1988008704 A3 WO 1988008704A3 GB 8800350 W GB8800350 W GB 8800350W WO 8808704 A3 WO8808704 A3 WO 8808704A3
Authority
WO
WIPO (PCT)
Prior art keywords
antacid
cimetidine
pharmaceutical compositions
water
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1988/000350
Other languages
English (en)
Other versions
WO1988008704A2 (fr
Inventor
Gordon France
Graham Stanley Leonard
Kevin Edward Pearmain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to JP63503931A priority Critical patent/JPH0645540B2/ja
Priority to KR1019890700008A priority patent/KR890701102A/ko
Publication of WO1988008704A2 publication Critical patent/WO1988008704A2/fr
Priority to DK726588A priority patent/DK726588A/da
Publication of WO1988008704A3 publication Critical patent/WO1988008704A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dosage pharmaceutique sous forme solide comprenant: (i) de la cimétidine, et (ii) de l'antacide, dans lequel au moins une partie de l'antacide se présente sous la forme de granules comprenant un diluant solide librement soluble dans l'eau, l'antacide, ainsi qu'un désintégrant insoluble dans l'eau pouvant se dilater rapidement. Les compositions de ce type surmontent le problème de la biodisponibilité réduite de la cimétidine, pouvant se produire lorsque la cimétidine est administrée conjointement avec des antacides.
PCT/GB1988/000350 1987-05-08 1988-05-04 Compositions pharmaceutiques Ceased WO1988008704A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP63503931A JPH0645540B2 (ja) 1987-05-08 1988-05-04 医薬組成物
KR1019890700008A KR890701102A (ko) 1987-05-08 1988-05-04 제약학적 조성물
DK726588A DK726588A (da) 1987-05-08 1988-12-28 Farmaceutiske midler

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8710965 1987-05-08
GB878710965A GB8710965D0 (en) 1987-05-08 1987-05-08 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO1988008704A2 WO1988008704A2 (fr) 1988-11-17
WO1988008704A3 true WO1988008704A3 (fr) 1989-02-09

Family

ID=10617055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1988/000350 Ceased WO1988008704A2 (fr) 1987-05-08 1988-05-04 Compositions pharmaceutiques

Country Status (13)

Country Link
US (1) US5169640A (fr)
JP (1) JPH0645540B2 (fr)
KR (1) KR890701102A (fr)
AU (1) AU602583B2 (fr)
CA (1) CA1304685C (fr)
DE (1) DE3868986D1 (fr)
ES (1) ES2032963T3 (fr)
GB (1) GB8710965D0 (fr)
GR (1) GR3004356T3 (fr)
IE (1) IE60948B1 (fr)
PT (1) PT87422B (fr)
WO (1) WO1988008704A2 (fr)
ZA (2) ZA883167B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
KR960011236B1 (ko) * 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
DE19529862A1 (de) * 1995-08-14 1997-02-20 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
TW469135B (en) * 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DE69739967D1 (de) * 1996-06-14 2010-09-30 Kyowa Hakko Kirin Co Ltd Eine im Mund schnell zerfallende Tablette
JP3001440B2 (ja) * 1996-11-25 2000-01-24 日本電気通信システム株式会社 仮想ｌａｎ方式
US6096834A (en) * 1997-04-04 2000-08-01 Monsanto Company Hydrolyzable delivery system using crosslinked polymeric resins as vehicles
US6471955B1 (en) 1997-04-04 2002-10-29 Pharmacia Corporation Ph-selective delivery system using crosslinked polymeric resins as vehicles
US6890524B1 (en) 1997-04-04 2005-05-10 Monsanto Company Hydrolyzable delivery system using cross-linked polymeric resins as vehicles
US5939091A (en) * 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
AU2002247019C1 (en) 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (fr) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2009520704A (ja) * 2005-12-21 2009-05-28 エーディーディー アドバンスト ドラッグ デリバリー テクノロジーズ リミテッド 水溶性担体を持つコアを含むペレット
WO2007090113A2 (fr) 2006-02-01 2007-08-09 Weg Stuart L Utilisation de compositions antifongiques pour traiter des conditions gastro-intestinales superieures
WO2009095210A1 (fr) * 2008-01-31 2009-08-06 Bayer Consumer Care Ag Composition comprenant un antiacide et des antagonistes h2
ES2357209B1 (es) * 2009-05-26 2011-12-07 Fundacion Universitaria San Pablo-Ceu Composición farmacéutica sólida a base de famotidina contra la hipersecreción gástrica y otras enfermedades relacionadas, con mayor eficacia sinérgica y más rápida actuación.
EP2506836B1 (fr) 2009-12-02 2018-02-14 Adare Pharmaceuticals S.R.L. Microcapsules de fexofénadine et compositions les contenant
JP6018911B2 (ja) * 2012-12-27 2016-11-02 ライオン株式会社 顆粒剤、カプセル剤
TWI724629B (zh) * 2018-11-16 2021-04-11 日商協和化學工業股份有限公司 緩瀉用錠劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6885M (fr) * 1965-12-06 1969-04-21
EP0003589A2 (fr) * 1978-02-06 1979-08-22 The Wellcome Foundation Limited Formule pour comprimés d'antiacide
EP0138540A2 (fr) * 1983-10-10 1985-04-24 SMITH KLINE DAUELSBERG GmbH Compositions pharmaceutiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681756A (en) * 1981-04-29 1987-07-21 Hoffman-La Roche Inc. Prevention of N-nitroso compound formation in vivo
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
KR960011236B1 (ko) * 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6885M (fr) * 1965-12-06 1969-04-21
EP0003589A2 (fr) * 1978-02-06 1979-08-22 The Wellcome Foundation Limited Formule pour comprimés d'antiacide
EP0138540A2 (fr) * 1983-10-10 1985-04-24 SMITH KLINE DAUELSBERG GmbH Compositions pharmaceutiques

Also Published As

Publication number Publication date
KR890701102A (ko) 1989-12-19
JPH02500747A (ja) 1990-03-15
GR3004356T3 (fr) 1993-03-31
ES2032963T3 (es) 1993-03-01
CA1304685C (fr) 1992-07-07
IE881369L (en) 1988-11-08
US5169640A (en) 1992-12-08
ZA883167B (en) 1990-02-28
AU602583B2 (en) 1990-10-18
WO1988008704A2 (fr) 1988-11-17
PT87422B (pt) 1992-08-31
DE3868986D1 (de) 1992-04-16
AU1714188A (en) 1988-12-06
JPH0645540B2 (ja) 1994-06-15
PT87422A (pt) 1989-05-31
ZA883212B (en) 1989-03-29
IE60948B1 (en) 1994-09-07
GB8710965D0 (en) 1987-06-10

Similar Documents

Publication Publication Date Title
WO1988008704A3 (fr) Compositions pharmaceutiques
EP0294933A3 (en) Pharmaceutical compositions
EP1287822A3 (fr) Compositions pharmaceutiques orales à liberation régulée à base de mésalazine
IE862785L (en) Effervescent ibuprofen composition
CA2024291A1 (fr) Dispositif de dosage et preparation et utilisation de celui-ci
CA2102630A1 (fr) Compositions pharmaceutiques de medicaments compactes
IL91404A0 (en) Substituted 4-azatricyclo(22.3.1.0 4,9)octacos-18-ene derivations,their preparation and pharmaceutical compositions containing them
IE881368L (en) Pharmaceutical compositions
EP0189861A3 (fr) Promoteur d'absorption percutannée pour des médicaments ioniques hydrosolubles
IE871584L (en) Sustained release capsule.
IE881916L (en) Press-coated dihydropyridine tablets
CA2004598A1 (fr) Aerosols medicinaux
HK48392A (en) Drug particles having constant release and immediate release
CA2000763A1 (fr) Produit dispersant
CA2164776A1 (fr) Composition pharmaceutique, administrable par voie orale
WO2003080023A3 (fr) Formes posologiques a dissolution rapide presentant une friabilite reduite
AU2915789A (en) Pharmaceutical compositions
CA2265767A1 (fr) Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane
EP0070178A3 (fr) Nouvelles formulations du bendrofluméthiazide
HK60192A (en) Drug particles having constant release
CA2110166A1 (fr) Fabrication de comprimes d'hydrochloride de colestipol
CA2114859A1 (fr) Compose cytotoxique et antiviral
EP0297547A3 (fr) Emploi de tannates hydrolysables pour le traitement et la prophylaxie du SIDA
EP0209843A3 (fr) Composés de benzylpipérazine, sa préparation, composition pharmaceutique et utilisation
WO1994006454A3 (fr) Inhibition d'infection retrovirale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK JP KR US

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK JP KR US